U.S., June 24 -- ClinicalTrials.gov registry received information related to the study (NCT07661979) titled 'Opzelura Experience Study' on June 17.
Brief Summary: Atopic dermatitis is a common multifactorial skin disease. Topicals are the mainstay of treatment, but adherence to topicals is often abysmal, possibly worsened by the complexity of recommended treatment algorithms. Giving patients a simple, one drug approach may be advantageous.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
DRUG: ruxolitinib
patients are directed to apply topical ruxolitinib (Opzelura) twice daily to all affected areas until clear, then as needed
DRUG: ruxolitinib and an Eczema Action Plan
patients wi...